Endometrial safety and efficacy of ospemifene

Steven R. Goldstein
Menopause (New York, N.Y.) · 2023 · vol. 30(8) , pp. 788–790 · doi:10.1097/gme.0000000000002225 · PMID:37467145 · W4384695680
Other OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-16 ⓘ

The provided text contains only metadata regarding the authors, funding, and contact information for a paper on the endometrial safety of ospemifene, without reporting any specific research findings or results.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

From the NYU School of Medicine, New York, NY. Received May 23, 2023; revised and accepted May 24, 2023. Funding/support: None reported. Financial disclosure/conflicts of interest: None reported. Address correspondence to: Steven R. Goldstein, MD, CCD, NCMP, FACOG, FRCOG(H), Ob/Gyn, NYU Grossman School of Medicine, 314 East 34 Street, 5th Floor, New York 10016, NY. E-mail: [email protected]

My notes (saved in your browser only)

MeSH descriptors

Selective Estrogen Receptor Modulators Tamoxifen Tamoxifen Tamoxifen Atrophy Atrophy Endometrium Endometrium Female Humans Vagina Vagina Vulva Vulva

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (8)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:40:31.801315+00:00
unpaywall
last seen: 2026-10-11T06:28:45.473802+00:00
License: CC0 · commercial use OK